Clinical Trial Details
| Trial ID: | L3071 |
| Source ID: | NCT00044148 |
| Associated Drug: | Ly333531 |
| Title: | The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetic Nephropathy |
| Interventions: | DRUG: LY333531 |
| Outcome Measures: | |
| Sponsor/Collaborators: | Sponsor: Chromaderm, Inc. |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT |
| Start Date: | 2002-07-16 |
| Completion Date: | 2004-04-28 |
| Results First Posted: | |
| Last Update Posted: | 2017-02-01 |
| Locations: | La Jolla, California, United States|Walnut Creek, California, United States|Jacksonville, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Lexington, Kentucky, United States|Baltimore, Maryland, United States|Waltham, Massachusetts, United States|Minneapolis, Minnesota, United States|St Louis, Missouri, United States|New York, New York, United States|Greenville, North Carolina, United States|Dallas, Texas, United States|Seattle, Washington, United States|Spokane, Washington, United States |
| URL: | https://clinicaltrials.gov/show/NCT00044148 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|